Updating results

2725 results

Sort: Relevance | Date

Impella 2.5 for haemodynamic support during high-risk percutaneous coronary interventions (MIB89)

Advice on the use of Impella 2.5 for haemodynamic support during high-risk percutaneous coronary interventions to aid local decision-making

Medtech innovation briefing Published November 2016

C3 glomerulopathy in the native kidney: eculizumab (ESUOM49)

Summary of the evidence on eculizumab for treating C3 glomerulopathy in the native kidney inform local NHS planning and decision-making

Evidence summary Published December 2015

Infantile haemangioma: topical timolol (ESUOM47)

Summary of the evidence on topical timolol for treating infantile haemangioma (strawberry marks) to inform local NHS planning and decision-making

Evidence summary Published August 2015

Hypersexuality: fluoxetine (ESUOM46)

Summary of the evidence on fluoxetine for treating hypersexuality to inform local NHS planning and decision-making

Evidence summary Published July 2015

Symptoms of peripheral arterial disease: ramipril (ESUOM45)

Summary of the evidence on ramipril for relieving the symptoms of peripheral arterial disease (PAD) to inform local NHS planning and decision-making

Evidence summary Published June 2015

Prevention of recurrence of C3 glomerulopathy post-transplant: eculizumab (ESUOM44)

Summary of the evidence on eculizumab to prevent the recurrence of C3 glomerulopathy post-transplant to inform local NHS planning and decision-making

Evidence summary Published June 2015

Digital ulcers: sildenafil (ESUOM42)

Summary of the evidence on sildenafil for managing digital ulcers to inform local NHS planning and decision-making

Evidence summary Published March 2015

Management of aggression, agitation and behavioural disturbances in dementia: carbamazepine (ESUOM40)

Summary of the evidence on carbamazepine for managing aggression, agitation and behavioural disturbances in people with dementia..

Evidence summary Published March 2015

Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate (ESUOM4)

Summary of the evidence on oral magnesium glycerophosphate for preventing recurrent hypomagnesaemia to inform local NHS planning and decision-making

Evidence summary Published January 2013

Autoimmune haemolytic anaemia: rituximab (ESUOM39)

Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making

Evidence summary Published February 2015

Non-cystic fibrosis bronchiectasis: long-term azithromycin (ESUOM38)

Summary of the evidence on long-term azithromycin for treating non-cystic fibrosis bronchiectasis to inform local NHS planning and decision-making

Evidence summary Published November 2014

Cystic fibrosis: long-term azithromycin (ESUOM37)

Summary of the evidence on long-term azithromycinoral for treating cystic fibrosis (CF) to inform local NHS planning and decision-making

Evidence summary Published November 2014

Systemic lupus erythematosus: oral mycophenolate (ESUOM36)

Summary of the evidence on oral mycophenolate for systemic lupus erythematosus (SLE) to inform local NHS planning and decision-making

Evidence summary Published November 2014

Immune (idiopathic) thrombocytopenic purpura: rituximab (ESUOM35)

Summary of the evidence on rituximab for immune (idiopathic) thrombocytopenic purpura in adults to inform local NHS planning and decision-making

Evidence summary Published October 2014

Management of vomiting in children and young people with gastroenteritis: ondansetron (ESUOM34)

Summary of the evidence on ondansetron for the management of vomiting in children and young people with acute gastroenteritis...

Evidence summary Published October 2014

Migraine prophylaxis: flunarizine (ESUOM33)

Summary of the evidence on flunarizine for treating migraine prophylaxis to inform local NHS planning and decision-making

Evidence summary Published September 2014

Scleroderma: oral mycophenolate (ESUOM32)

Summary of the evidence on oral mycophenolate for systemic sclerosis (scleroderma) to inform local NHS planning and decision-making

Evidence summary Published July 2014

Chronic urticaria: off-label doses of cetirizine (ESUOM31)

Summary of the evidence on off-label doses of cetirizine for chronic urticaria (hives) to inform local NHS planning and decision-making

Evidence summary Published July 2014

Pouchitis: rifaximin (ESUOM30)

Summary of the evidence on rifaximin for treating pouchitis to inform local NHS planning and decision-making

Evidence summary Published March 2014

Chronic anal fissure: 2% topical diltiazem hydrochloride (ESUOM3)

Summary of the evidence on 2% topical diltiazem hydrochloride for chronic anal fissure to inform local NHS planning and decision-making

Evidence summary Published January 2013

Difficult-to-treat scabies: oral ivermectin (ESUOM29)

Summary of the evidence on oral ivermectin for treating difficult-to-treat scabies to inform local NHS planning and decision-making

Evidence summary Published March 2014

Chronic pain: oral ketamine (ESUOM27)

Summary of the evidence on oral ketamine for treating chronic pain to inform local NHS planning and decision-making

Evidence summary Published February 2014 Last updated June 2014

Interstitial cystitis: dimethyl sulfoxide bladder instillation (ESUOM26)

Summary of the evidence on dimethyl sulfoxide bladder instillation for treating interstitial cystitis to inform local NHS planning and decision-making

Evidence summary Published February 2014

Non-cystic fibrosis bronchiectasis: colistimethate sodium (ESUOM25)

Summary of the evidence on colistimethate sodium (Colobreathe) for non-cystic fibrosis bronchiectasis to inform local NHS planning and decision-making

Evidence summary Published January 2014

Transient ischaemic attack: clopidogrel (ESUOM23)

Summary of the evidence on clopidogrel for treating transient ischaemic attack (TIA) to inform local NHS planning and decision-making

Evidence summary Published December 2013

Bile acid malabsorption: colesevelam (ESUOM22)

Summary of the evidence on colesevelam for treating bile acid malabsorption (BAM) to inform local NHS planning and decision-making

Evidence summary Published October 2013

Ovarian cancer (advanced): bevacizumab 7.5 mg/kg in combination with paclitaxel and carboplatin for first-line treatment (ESUOM21)

Summary of the evidence on bevacizumab 7.5 mg/kg with paclitaxel and carboplatin for the first-line treatment of advanced ovarian cancer..

Evidence summary Published October 2013

Postural hypotension in adults: fludrocortisone (ESUOM20)

Summary of the evidence on fludrocortisone for treating postural hypotension in adults to inform local NHS planning and decision-making

Evidence summary Published October 2013

Sleep disorders in children and young people with attention deficit hyperactivity disorder: melatonin (ESUOM2)

Summary of the evidence on melatonin for sleep disorders in children and young people with attention deficit hyperactivity disorder (ADHD)..

Evidence summary Published January 2013

Orthostatic hypotension due to autonomic dysfunction: midodrine (ESNM61)

Summary of the evidence on midodrine for orthostatic hypotension due to autonomic dysfunction to inform local NHS planning and decision-making

Evidence summary Published October 2015

Type 2 diabetes: insulin degludec/liraglutide (Xultophy) (ESNM60)

Summary of the evidence on insulin degludec/liraglutide (Xultophy) for treating type 2 diabetes to inform local NHS planning and decision-making

Evidence summary Published July 2015

Type 2 diabetes: dulaglutide (ESNM59)

Summary of the evidence on dulaglutide for treating type 2 diabetes to inform local NHS planning and decision-making

Evidence summary Published June 2015

Ulcerative colitis: budesonide multimatrix (Cortiment) (ESNM58)

Summary of the evidence on budesonide multimatrix (Cortiment) for treating ulcerative colitis (UC) to inform local NHS planning and decision-making

Evidence summary Published June 2015

Chronic obstructive pulmonary disease: aclidinium/formoterol (ESNM57)

Summary of the evidence on aclidinium/formoterol for chronic obstructive pulmonary disease (COPD) to inform local NHS planning and decision-making

Evidence summary Published April 2015

Glaucoma: brinzolamide/brimonidine combination eye drops (ESNM56)

Summary of the evidence on brinzolamide/brimonidine combination eye drops for treating glaucoma to inform local NHS planning and decision-making

Evidence summary Published March 2015

Asthma: tiotropium (Spiriva Respimat) (ESNM55)

Summary of the evidence on tiotropium (Spiriva Respimat) for treating asthma to inform local NHS planning and decision-making

Evidence summary Published March 2015

Chronic obstructive pulmonary disease: olodaterol (ESNM54)

Summary of the evidence on olodaterol for treating chronic obstructive pulmonary disease (COPD) to inform local NHS planning and decision-making

Evidence summary Published February 2015

Asthma in adults: beclometasone/formoterol dry powder inhaler (Fostair NEXThaler) (ESNM53)

Summary of the evidence on beclometasone/formoterol dry powder inhaler (Fostair NEXThaler) for treating asthma in adults..

Evidence summary Published January 2015

Chronic obstructive pulmonary disease: umeclidinium inhaler (Incruse) (ESNM52)

Summary of the evidence on umeclidinium inhaler (Incruse) for chronic obstructive pulmonary disease to inform local NHS planning and decision-making

Evidence summary Published January 2015

Hyperphosphataemia in adults with chronic kidney disease on dialysis: sucroferric oxyhydroxide (ESNM51)

Summary of the evidence on sucroferric oxyhydroxide for treating hyperphosphataemia in adults with chronic kidney disease (CKD) on dialysis..

Evidence summary Published January 2015

Erectile dysfunction: Alprostadil cream (ESNM50)

Summary of the evidence on alprostadil cream for treating erectile dysfunction to inform local NHS planning and decision-making

Evidence summary Published December 2014

Chronic obstructive pulmonary disease: umeclidinium/vilanterol combination inhaler (Anoro Ellipta) (ESNM49)

Summary of the evidence on umeclidinium/vilanterol combination inhaler (Anoro Ellipta) for treating chronic obstructive pulmonary disease (COPD)...

Evidence summary Published November 2014

Schizophrenia: lurasidone (ESNM48)

Summary of the evidence on lurasidone (Latuda) for schizophrenia in adults aged 18 and over to inform local NHS planning and decision-making

Evidence summary Published September 2014

Chronic obstructive pulmonary disease: beclometasone/formoterol (Fostair) (ESNM47)

Summary of the evidence on beclometasone/formoterol (Fostair) for treating chronic obstructive pulmonary disease (COPD)...

Evidence summary Published September 2014

Non-Hodgkin's lymphoma: rituximab subcutaneous injection (ESNM46)

Summary of the evidence on rituximab subcutaneous injection for non-Hodgkin's lymphoma in adults to inform local NHS planning and decision-making

Evidence summary Published September 2014

Fatigue in multiple sclerosis: modafinil (ESUOM9)

Summary of the evidence on modafinil for treating fatigue in multiple sclerosis (MS) to inform local NHS planning and decision-making

Evidence summary Published April 2013

Attention deficit hyperactivity disorder in children and young people: clonidine (ESUOM8)

Summary of the evidences on clonidine for attention deficit hyperactivity disorder (ADHD) in children and young people..

Evidence summary Published April 2013

Chronic anal fissure: 0.2% topical glyceryl trinitrate ointment (ESUOM7)

Summary of the evidence on 0.2% topical glyceryl trinitrate ointment for chronic anal fissure to inform local NHS planning and decision-making

Evidence summary Published March 2013

Polycystic ovary syndrome: metformin in women not planning pregnancy (ESUOM6)

Summary of the evidence on metformin for polycystic ovary syndrome (PCOS) in women not planning pregnancy to inform local NHS planning and decision-making

Evidence summary Published February 2013

Pulmonary hypertension in neonates: sildenafil (ESUOM51)

Summary of the evidence on sildenafil for treating pulmonary hypertension in neonates to inform local NHS planning and decision-making

Evidence summary Published March 2016